Tirzepatide acts on GIP and GLP-1 receptors. Its approved uses depend on the product and jurisdiction, rather than following automatically from its dual-receptor mechanism.
SURMOUNT-1 studied adults with obesity or overweight without diabetes. SURMOUNT-5 directly compared specified maximum-tolerated tirzepatide and semaglutide regimens, with an open-label design. Neither trial compares every later formulation or settles suitability for an individual.
The US sleep-apnea approval has a defined adult population. It is not advice to stop positive-airway-pressure treatment independently. The appropriate care team should review changes.
The applicable label remains the source for contraindications and warnings. This profile does not recommend combining medicines, selecting a dose, or substituting products.
Regulatory status checked on 3 October 2026
United States: Zepbound is FDA-approved for specified adult weight-management uses and moderate-to-severe obstructive sleep apnea in adults with obesity. Product-label restrictions apply.
European Union: EMA Mounjaro record documents EU authorisation for specified diabetes and adult weight-management uses. The US and EU product indications are independently described.
Official records and primary evidence
- US Zepbound prescribing information — Eli Lilly
- FDA Zepbound sleep-apnea indication — FDA
- EU Mounjaro product record — EMA
- SURMOUNT-1 obesity trial — SURMOUNT-1 investigators / NEJM
- SURMOUNT-5 direct comparison — SURMOUNT-5 investigators / NEJM
Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.